DUBLIN, Calif., Dec. 4 /PRNewswire/ -- Microchip Biotechnologies, a private company developing the Apollo next-generation fluidics platform for Life Sciences, announced today that Ezra Van Gelder has joined its team as Executive Vice President of R&D.
Ezra Van Gelder brings Microchip Biotechnologies (MBI) extensive leadership experience in research and development from the life science, medical device and semiconductor equipment industries. Prior to joining MBI, Ezra Van Gelder headed instrument and reagent development for DNA and RNA sample preparation at Arcxis Biosciences. At Molecular Dynamics, Amersham and GE Healthcare, where he was VP of Development for the West Coast, he led development for DNA sequencing and cell analysis. In the semiconductor industry Ezra Van Gelder directed the development of automated optical wafer inspection equipment at KLA Instruments and KLA-Tencor.
“The addition of Ezra Van Gelder, as Executive VP of R&D, further strengthens the world class team at MBI. Ezra brings considerable expertise in developing innovative next generation life science solutions focused on end users and implementing product development processes and ISO 13485,” said Dr. Stevan Jovanovich, President and CEO of Microchip Biotechnologies. “Ezra’s R&D leadership and experience will accelerate the full integration of sample preparation and analysis on MBI’s Apollo platform.”
“I have spent much of my career working on separate reagent and analytical instrumentation systems, so I am now relishing the prospect of working with a platform that can genuinely integrate macro and microfluidics to provide much needed, complete sample-to-answer solutions,” said Ezra Van Gelder. “The Apollo platform, along with the exceptional group at MBI, will bring new capabilities to life sciences, diagnostics and compact field portable devices for life science applications.”
Ezra Van Gelder holds a B.Sc. in Mechanical Engineering from Tel Aviv University, Israel and a M.Sc. in Mechanical Engineering from Santa Clara University, California, USA.
About Microchip Biotechnologies
Microchip Biotechnologies, Inc., also known as MBI, is a privately-held company that is located in Dublin, California. The company is developing the Apollo next-generation fluidics platform for life sciences, applied sciences, and diagnostics markets. The Apollo platform integrates advanced microfluidic sample preparation, and analytical capabilities, to produce sample-to-answer performance for DNA sequencing, biodefense, DNA-based forensics and human identity (HID), and molecular diagnostics applications. The platform incorporates MBI’s proprietary BeadStorm(TM) bead-based sample preparation devices and ‘Microscale On-Chip Valve’ (MOVe(TM)) valves, pumps, and routers on NanoPulse(TM) microchips. More details about the MBI, its technologies and products can be found at: www.microchipbiotech.com.
CONTACT: Dr. Barney E. Saunders of Microchip Biotechnologies, Inc. (MBI),
+1-925-574-7304, Barney.saunders@microchipbiotech.com
Web site: http://www.microchipbiotech.com/
